Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity

Carbone PP: Breast cancer. In HM Pinedo and BA Chabner (eds): The EORTC Cancer Chemotherapy Annual 5. Elsevier, Amsterdam, 1983, pp398–422

Smalley RV, Lefante J, Bartolucci A: CAF vs CMFVP in patients with advanced breast cancer. Proc Am Soc Clin Oncol 22:444, 1981

Godrey TE: Mitomycin-C in breast cancer. In SK Carter and ST Crooke (eds): Mitomycin-C — Current Status and New Developments. Academic Press, New York, 1979, pp91–100

Davis TE, Carbone PP: Drug treatment of breast cancer. Drugs 16:441, 1978

Stuart-Harris RC, Bozek T, Pavlidis NA, Smith IE: Mitoxantrone: An active new agent in the treatment of advanced breast cancer. Cancer Chemother Pharmacol 12:1–4, 1984

Coleman RE, Rubens RD, Knight RK, Maisey MN: Mitoxantrone in advanced breast cancer — a phase II study with special attention to cardiotoxicity. Br J Cancer 49:390, 1984

Neidhart JA, Gochnour D, Young DC: Mitoxantrone versus doxorubicin in advanced breast cancer: a randomised cross-over trial. Cancer Treat Rev 10 (Suppl B):47–52, 1983

Oster MW, Park Y, Grossbard L: Vincristine (V) and mitomycin (M) therapy for previously treated breast cancer. Proc Am Soc Clin Oncol 22:448, 1981

World Health Organisation: WHO handbook for reporting results of cancer treatment. WHO offset publication no.48, Geneva, 1979

Crossley RJ: Clinical safety and tolerance of mitoxantrone (Novantrone). Cancer Treat Rev 10 (Suppl B):29–36, 1983

Pavy MD, Wiely EL, Abeloff MD: Haemolytic-uraemic syndrome associated with mitomycin therapy. Cancer Treat Rep 66:457, 1982

Baker LH, Vaitkevicius VK: The development of an acute intermittent schedule — Mitomycin-C. In SK Carter and ST Crooke (eds): Mitomycin-C — Current Status and New Developments. Academic Press, New York, 1979, pp77–82